scispace - formally typeset
Open AccessJournal ArticleDOI

Left Ventricular Remodeling After Myocardial Infarction Pathophysiology and Therapy

Martin St. John Sutton, +1 more
- 27 Jun 2000 - 
- Vol. 101, Iss: 25, pp 2981-2988
Reads0
Chats0
TLDR
This article will review postinfarction remodeling, pathophysiological mechanisms, and therapeutic intervention in left ventricular remodeling and provide important insights into the remodeling process and a rationale for future therapeutic strategies.
Abstract
Left ventricular remodeling is the process by which ventricular size, shape, and function are regulated by mechanical, neurohormonal, and genetic factors.1 2 Remodeling may be physiological and adaptive during normal growth or pathological due to myocardial infarction, cardiomyopathy, hypertension, or valvular heart disease (Figure 1⇓). This article will review postinfarction remodeling, pathophysiological mechanisms, and therapeutic intervention. Figure 1. Diagrammatic representation of the many factors involved in the pathophysiology of ventricular remodeling. ECM indicates extracellular matrix; RAAS, renin-angiotensin-aldosterone system; CO, cardiac output; SVR, systemic vascular resistance; LV, left ventricular; and AII, angiotensin II. ### Postinfarction Left Ventricular Remodeling The acute loss of myocardium results in an abrupt increase in loading conditions that induces a unique pattern of remodeling involving the infarcted border zone and remote noninfarcted myocardium. Myocyte necrosis and the resultant increase in load trigger a cascade of biochemical intracellular signaling processes that initiates and subsequently modulates reparative changes, which include dilatation, hypertrophy, and the formation of a discrete collagen scar. Ventricular remodeling may continue for weeks or months until the distending forces are counterbalanced by the tensile strength of the collagen scar. This balance is determined by the size, location, and transmurality of the infarct, the extent of myocardial stunning, the patency of the infarct-related artery, and local tropic factors.1 3 The myocardium consists of 3 integrated components: myocytes, extracellular matrix, and the capillary microcirculation that services the contractile unit assembly. Consideration of all 3 components provides important insights into the remodeling process and a rationale for future therapeutic strategies. The cardiomyocyte is terminally differentiated and develops tension by shortening. The extracellular matrix provides a stress-tolerant, viscoelastic scaffold consisting of type I and type III collagen that couples myocytes and maintains the spatial relations between the myofilaments and their capillary microcirculation.4 5 The collagen framework couples adjacent myocytes by intercellular struts that …

read more

Citations
More filters
Journal ArticleDOI

Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling

TL;DR: Left ventricular end-diastolic and end-systolic volume and ejection fraction data provide support for the beneficial effects of therapeutic agents such as angiotensin-converting enzyme (ACE) inhibitors and beta-adrenergic blocking agents on the remodeling process.
Journal ArticleDOI

The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions

TL;DR: This work identifies two distinct phases of monocyte participation after MI and proposes a model that reconciles the divergent properties of these cells in healing and identifies new therapeutic targets that can influence healing and ventricular remodeling after MI.
Journal ArticleDOI

Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?

Aimun Ahmed, +2 more
- 24 Jun 2016 - 
TL;DR: The STOP ACEi trial will strengthen the evidence base and shed light on the potential merits and dangers of ACEi/ARB use in advanced CKD on renal function and cardiovascular outcomes.
Journal ArticleDOI

The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis

TL;DR: The renin-angiotensin-aldosterone system and members of the transforming growth factor-β family play an important role in activation of infarct myofibroblasts, and therapeutic modulation of the inflammatory and reparative response may hold promise for the prevention of postinfarction heart failure.
References
More filters
Journal ArticleDOI

Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications.

TL;DR: The extent of ventricular enlargement after infarction is related to the magnitude of the initial damage to the myocardium and, although an increase in cavity size tends to restore stroke volume despite a persistently depressed ejection fraction, ventricular dilation has been associated with a reduction in survival.
Journal ArticleDOI

Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction.

TL;DR: Volume, ejection fractions, and severity of coronary arterial occlusions and stenoses in 605 male patients under 60 years of age at 1 to 2 months after a first or recurrent myocardial infarction showed that end-systolic volume had greater predictive value for survival than end-diastolic volume or ejection fraction.
Journal ArticleDOI

Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts.

TL;DR: It is shown that the subcutaneous administration of transforming growth factor- beta 1 to rats results in the formation of a granulation tissue in which alpha-SM actin expressing myofibroblasts are particularly abundant, suggesting that TGF beta 1 plays an important role in my ofibroblast differentiation during wound healing and fibrocontractive diseases by regulating the expression of alpha- SM actin in these cells.
Journal Article

Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators

Gordon Murray
- 02 Oct 1993 - 
TL;DR: There remains a substantial subgroup of patients who manifest clinical evidence of heart failure despite the first two of these treatments, despite survival after acute myocardial infarction being enhanced by treatment with thrombolytic agents, aspirin, and Beta -adrenoceptor blockade.
Related Papers (5)